Protein A immunoadsorption therapy for refractory, mitomycin C–associated thrombotic microangiopathy
Stefan Kasper
From the Third Medical Department (Hematology/Oncology) and the First Medical Department (Gastroenterology/Nephrology), Johannes Gutenberg-University Mainz, Mainz, Germany.
Search for more papers by this authorMarkus F. Neurath
From the Third Medical Department (Hematology/Oncology) and the First Medical Department (Gastroenterology/Nephrology), Johannes Gutenberg-University Mainz, Mainz, Germany.
Search for more papers by this authorChristoph Huber
From the Third Medical Department (Hematology/Oncology) and the First Medical Department (Gastroenterology/Nephrology), Johannes Gutenberg-University Mainz, Mainz, Germany.
Search for more papers by this authorMatthias Theobald
From the Third Medical Department (Hematology/Oncology) and the First Medical Department (Gastroenterology/Nephrology), Johannes Gutenberg-University Mainz, Mainz, Germany.
Search for more papers by this authorInge Scharrer
From the Third Medical Department (Hematology/Oncology) and the First Medical Department (Gastroenterology/Nephrology), Johannes Gutenberg-University Mainz, Mainz, Germany.
Search for more papers by this authorStefan Kasper
From the Third Medical Department (Hematology/Oncology) and the First Medical Department (Gastroenterology/Nephrology), Johannes Gutenberg-University Mainz, Mainz, Germany.
Search for more papers by this authorMarkus F. Neurath
From the Third Medical Department (Hematology/Oncology) and the First Medical Department (Gastroenterology/Nephrology), Johannes Gutenberg-University Mainz, Mainz, Germany.
Search for more papers by this authorChristoph Huber
From the Third Medical Department (Hematology/Oncology) and the First Medical Department (Gastroenterology/Nephrology), Johannes Gutenberg-University Mainz, Mainz, Germany.
Search for more papers by this authorMatthias Theobald
From the Third Medical Department (Hematology/Oncology) and the First Medical Department (Gastroenterology/Nephrology), Johannes Gutenberg-University Mainz, Mainz, Germany.
Search for more papers by this authorInge Scharrer
From the Third Medical Department (Hematology/Oncology) and the First Medical Department (Gastroenterology/Nephrology), Johannes Gutenberg-University Mainz, Mainz, Germany.
Search for more papers by this authorAbstract
BACKGROUND: Mitomycin C–associated thrombotic microangiopathy (TMA) has a poor prognosis with limited therapeutic options. Most patients die within 4 months of diagnosis due to pulmonary or renal failure. Here, a patient resistant to total plasma exchange (TPE) and immunosuppressive therapy with glucocorticoids, rituximab, vincristine, and splenectomy who was successfully treated with protein A immunoadsorption is described.
CASE REPORT: A 29-year-old woman developed a TMA after chemotherapy with mitomycin C. She presented with thrombocytopenia, pulmonary edema, hemolytic anemia with presence of schistocytes, and renal failure. Immediate TPE (>120 times) and immunosuppressive therapy with glucocorticoids, however, did not improve her clinical situation. Furthermore, she was refractory to subsequent immunosuppressive therapy with rituximab and vincristine and laparoscopic splenectomy. Finally, after 12 cycles of extracorporeal protein A immunoadsorption with a commercially available immunoadsorption system (Immunosorba, Fresenius AG), platelet counts increased with disappearance of hemolytic syndromes.
CONCLUSION: Extracorporeal protein A immunoadsorption with the Immunosorba system emerges as a potentially effective and safe treatment for refractory mitomycin C–associated TMA with only moderate side effects. This therapeutic option may be considered at an early state of the disease to prevent extensive immunosuppression.
REFERENCES
- 1 Cantrell JE Jr, Phillips TM, Schein PS. Carcinoma-associated hemolytic–uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol 1985; 3: 723-34.
- 2 Doll DC, Weiss RB, Issell BF. Mitomycin: ten years after approval for marketing. J Clin Oncol 1985; 3: 276-86.
- 3
Sheldon R,
Slaughter D.
A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma.
Cancer
1986; 58: 1428-36.
10.1002/1097-0142(19861001)58:7<1428::AID-CNCR2820580709>3.0.CO;2-J PubMed Web of Science® Google Scholar
- 4 Murgo AJ. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol 1987; 24: 161-77.
- 5 Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989; 7: 781-9.
- 6 George JN. Tibor Greenwalt Award. The Oklahoma Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic Syndrome Registry: a program for patient care, education and research. Transfusion 2004; 44: 1384-92.
- 7 Kwaan HC. Thrombotic thrombocytopenic purpura: a diagnostic and therapeutic challenge. Semin Thromb Hemost 2005; 31: 615-24.
- 8 Veyradier A, Meyer D. Thrombotic thrombocytopenic purpura and its diagnosis. J Thromb Haemost 2005; 3: 2420-7.Review.
- 9
Snyder HW Jr,
Mittelman A,
Oral A, et al.
Treatment of cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma.
Cancer
1993; 71: 1882-92.
10.1002/1097-0142(19930301)71:5<1882::AID-CNCR2820710527>3.0.CO;2-E PubMed Web of Science® Google Scholar
- 10 Groff JA, Kozak M, Boehmer JP, Demko TM, Diamond JR. Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy. Am J Kidney Dis 1997; 29: 280-4.
- 11 Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001; 8: 286-93.
- 12 George JN. Clinical practice: thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-35.
- 13 Korec S, Schein PS, Smith FP, et al. Treatment of cancer-associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion. J Clin Oncol 1986; 4: 210-5.
- 14
Watson PR,
Guthrie TH Jr,
Caruana RJ.
Cisplatin-associated hemolytic-uremic syndrome: successful treatment with a staphylococcal protein A column.
Cancer
1989; 64: 1400-3.
10.1002/1097-0142(19891001)64:7<1400::AID-CNCR2820640705>3.0.CO;2-N CAS PubMed Web of Science® Google Scholar
- 15 Nand S, Molokie R. Therapeutic plasmapheresis and protein A immunoadsorption in malignancy: a brief review. J Clin Apher 1990; 5: 206-12.
- 16 Durand JM, Lefevre P. Mitomycin-induced thrombotic thrombocytopenic purpura: possible successful treatment with vincristine and cyclophosphamide. Haematologica 1991; 76: 421-3.
- 17
Mant MJ,
Turner AR,
Bruce D,
Ritchie C,
Larratt LM.
Splenectomy during partial remission in thrombotic thrombocytopenic purpura with prolonged plasma exchange dependency.
Am J Hematol
1999; 62: 56-7.
10.1002/(SICI)1096-8652(199909)62:1<56::AID-AJH10>3.0.CO;2-5 CAS PubMed Web of Science® Google Scholar
- 18 McCarthy LJ, Dlott JS, Orazi A, et al. Thrombotic thrombocytopenic purpura: yesterday, today, tomorrow. Ther Apher Dial 2004; 8: 80-6.
- 19 Rock G. The management of thrombotic thrombocytopenic purpura in 2005. Semin Thromb Hemost 2005; 31: 709-16.
- 20 George JN. Review of efficacy of rituximab and concurrent plasma exchange in the treatment of thrombotic thrombocytopenic purpura and recurrent thrombotic thrombocytopenic purpura treated repeatedly and successfully with the monoclonal antibody rituximab. Clin Adv Hematol Oncol 2006; 4: 217-8.
- 21 Hull MJ, Eichbaum QG. Efficacy of rituximab and concurrent plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Clin Adv Hematol Oncol 2006; 4: 210-4;discussion 217-8.
- 22 Bohm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann Hematol 2002; 81: 430-5.
- 23 Tripodi A, Chantarangkul V, Bohm M, et al. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas. J Thromb Haemost 2004; 2: 1601-9.
- 24 Gallerani E, Lerch E, Romagnani E, et al. Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab. Eur J Haematol 2006; 77: 527-9.
- 25 Yassa SK, Blessios G, Marinides G, Venuto RC. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome. Clin Transplant 2005; 19: 423-6.
- 26 Ferrara F, Annunziata M, Pollio F, et al. Vincristine as treatment for recurrent episodes of thrombotic thrombocytopenic purpura. Ann Hematol 2002; 81: 7-10.
- 27 Mateos J, Perez-Simon JA, Caballero D, et al. Vincristine is an effective therapeutic approach for transplantation-associated thrombotic microangiopathy. Bone Marrow Transplant 2006; 37: 337-8.
- 28 Bohm M, Betz C, Miesbach W, et al. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 2005; 129: 644-52.
- 29 McMinn JR Jr, Thomas IA, Terrell DR, et al. Complications of plasma exchange in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a study of 78 additional patients. Transfusion 2003; 43: 415-6.
- 30 De La Rubia J, Plume G, Arriaga F, et al. Platelet transfusion and thrombotic thrombocytopenic purpura. Transfusion 2002; 42: 1384-5.
- 31 Lozano M, Domingo A, Pereira A, Fontanals J, Mazzara R. Platelet transfusion in thrombotic thrombocytopenic purpura: between Scylla and Charybdis. Transfusion 2005; 45: 1984.
- 32 Aqui NA, Stein SH, Konkle BA, Abrams CS, Strobl FJ. Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. J Clin Apher 2003; 18: 51-4.
- 33 Kremer Hovinga JA, Studt JD, Demarmels Biasiutti F, et al. Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Haematologica 2004; 89: 320-4.
- 34 Kappers-Klunne MC, Wijermans P, Fijnheer R, et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2005; 130: 768-76.
- 35 Zeigler ZR, Shadduck RK, Nath R, Andrews DF 3rd. Pilot study of combined cryosupernatant and protein A immunoadsorption exchange in the treatment of grade 3-4 bone marrow transplant-associated thrombotic microangiopathy. Bone Marrow Transplant 1996; 17: 81-6.
- 36 Fontana S, Kremer Hovinga JA, Lammle B, Mansouri Taleghani B. Treatment of thrombotic thrombocytopenic purpura. Vox Sang 2006; 90: 245-54.
- 37 Toepfer M, Sitter T, Burchardi C, Held E, Schiffl H. [Clinical immunoadsorption]. Dtsch Med Wochenschr 1999; 124: 461-5.
- 38 Laurence J, Mitra D, Steiner M, Staiano-Coico L, Jaffe E. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells. Blood 1996; 87: 3245-54.
- 39 Seki Y, Toba K, Fuse I, et al. In vitro effect of cyclosporin A, mitomycin C and prednisolone on cell kinetics in cultured human umbilical vein endothelial cells. Thromb Res 2005; 115: 219-28.
Citing Literature
